These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 27432692)

  • 1. Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation.
    Saw J; Bennell MC; Singh SM; Wijeysundera HC
    Can J Cardiol; 2016 Nov; 32(11):1355.e9-1355.e14. PubMed ID: 27432692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
    Reddy VY; Akehurst RL; Armstrong SO; Amorosi SL; Brereton N; Hertz DS; Holmes DR
    Europace; 2016 Jul; 18(7):979-86. PubMed ID: 26838691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left Atrial Appendage Closure Device With Delivery System: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2017; 17(9):1-106. PubMed ID: 28744335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5-Year, Long-Term Data.
    Reddy VY; Akehurst RL; Gavaghan MB; Amorosi SL; Holmes DR
    J Am Heart Assoc; 2019 Jul; 8(13):e011577. PubMed ID: 31230500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk.
    Kawakami H; Nolan MT; Phillips K; Scuffham PA; Marwick TH
    Am Heart J; 2021 Jan; 231():110-120. PubMed ID: 32822655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
    Reddy VY; Akehurst RL; Amorosi SL; Gavaghan MB; Hertz DS; Holmes DR
    Stroke; 2018 Jun; 49(6):1464-1470. PubMed ID: 29739915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for Stroke Prevention in Patients with New-Onset Atrial Fibrillation.
    Micieli A; Wijeysundera HC; Qiu F; Atzema CL; Singh SM
    Med Decis Making; 2016 Apr; 36(3):366-74. PubMed ID: 26139448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Only Aspirin or Clopidogrel Following Percutaneous Left Atrial Appendage Closure.
    Pouru JP; Jaakkola S; Lund J; Biancari F; Saraste A; Airaksinen KEJ
    Am J Cardiol; 2019 Dec; 124(12):1894-1899. PubMed ID: 31668344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.
    Amorosi SL; Armstrong S; Da Deppo L; Garfield S; Stein K
    Europace; 2014 Aug; 16(8):1131-6. PubMed ID: 24687964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.
    Osmancik P; Herman D; Neuzil P; Hala P; Taborsky M; Kala P; Poloczek M; Stasek J; Haman L; Branny M; Chovancik J; Cervinka P; Holy J; Kovarnik T; Zemanek D; Havranek S; Vancura V; Opatrny J; Peichl P; Tousek P; Lekesova V; Jarkovsky J; Novackova M; Benesova K; Widimsky P; Reddy VY;
    J Am Coll Cardiol; 2020 Jun; 75(25):3122-3135. PubMed ID: 32586585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
    Singh SM; Micieli A; Wijeysundera HC
    Circulation; 2013 Jun; 127(24):2414-23. PubMed ID: 23697908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual antiplatelet therapy is safe and efficient after left atrial appendage closure.
    Maksym J; Mazurek T; Kochman J; Grygier M; Kapłon-Cieślicka A; Marchel M; Lodziński P; Piątkowski R; Wilimski R; Czub P; Fojt A; Karolczak N; Hendzel P; Opolski G
    Kardiol Pol; 2018; 76(2):459-463. PubMed ID: 29350390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure.
    Reddy VY; Akehurst RL; Armstrong SO; Amorosi SL; Beard SM; Holmes DR
    J Am Coll Cardiol; 2015 Dec; 66(24):2728-2739. PubMed ID: 26616031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of left atrial appendage closure with Watchman for non-valvular atrial fibrillation patients in Japan.
    Kamae I; Zhong Y; Hara H; Inoue K; Yasaka M; Reddy VY; Holmes DR; Sakurai M; Gavaghan MB; Amorosi SL; McGovern AM; Priest V; Inoue S; Shibahara H; Akehurst RL
    J Med Econ; 2023; 26(1):1357-1367. PubMed ID: 37819734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
    Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
    Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.
    Freeman JV; Hutton DW; Barnes GD; Zhu RP; Owens DK; Garber AM; Go AS; Hlatky MA; Heidenreich PA; Wang PJ; Al-Ahmad A; Turakhia MP
    Circ Arrhythm Electrophysiol; 2016 Jun; 9(6):. PubMed ID: 27307517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
    Wu B; Kun L; Liu X; He B
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left atrial appendage closure for prevention of death, stroke, and bleeding in patients with nonvalvular atrial fibrillation.
    Gloekler S; Saw J; Koskinas KC; Kleinecke C; Jung W; Nietlispach F; Meier B
    Int J Cardiol; 2017 Dec; 249():234-246. PubMed ID: 28882323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.